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the aGree instrument
Clinical guidelines are increasingly impor-
tant components in clinical practice. They 
are viewed as a means of translating 
research results into clinically relevant 
information and supporting physicians 
and patients in clinical decision making. 
Guidelines may reduce the discrepancies 
between scientific evidence and clinical 
practice, and in this way they can improve 
patient care. Using the AGREE instrument 
to develop and appraise current treatment 
guidelines might improve the quality of 
future guidelines.
methodological tools
Introducing tools for the critical apprais-
al of clinical research is important for 
improving the methodology of derma-
tological research and thus patient care. 
These tools include the CONSORT state-
ment (http://www.consort-statement.org) 
for randomized controlled trials; STROBE 
for observational studies (http://www.
strobe-statement.org); QUADAS, a tool 
developed to test the accuracy of diag-
nostic measurements; the QUOROM 
statement for improving the quality of 
reporting meta-analyses of randomized 
controlled trials; PRISMA (http://www.
prisma-statement.org), an evidence-based 
minimum set of items for reporting in 
systematic reviews and meta-analyses; 
AMSTAR for assessing the methodological 
quality of systematic reviews; and 
COSMIN for the selection of health status 
measurement instruments.
Two of the guidelines evaluated by 
Tan et al. in this issue have already been 
evaluated using AGREE, by Nast et al. 
(2009b). (These authors also assessed a 
Dutch evidence-based guideline that was 
excluded by Tan and colleagues because 
it was not published in English (Spuls 
et al., 2004; CBO, 2003).) Systematic 
reviews should not be restricted to 
English-language publications, to prevent 
bias. A Spanish psoriasis treatment guide-
line was not included by Tan et al. despite 
its being available online in English (Puig 
et al., 2009). It would have been use-
ful for the authors to provide a list of the 
excluded guidelines together with the 
reasons for exclusion. For example, it is 
unclear whether the Spanish evidence-
based guideline was intentionally omit-
ted. Surprisingly, Tan et al. did not search 
every database of evidence-based guide-
lines for inclusion in their study—the Trip 
database, Sumsearch, and the database 
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Tan et al. critically appraised the quality of eight guidelines for the treatment of 
psoriasis published by five working groups between 2006 and 2009, using the 
Appraisal of Guidelines Research and Evaluation (AGREE) instrument. Four groups 
used the standards established by the AGREE instrument. All guidelines received 
high scores for “scope and purpose” and “clarity and presentation,” but each of the 
guidelines was found to have important shortcomings in at least one item, including 
“stakeholder involvement,” “development rigor,” “applicability,” and “editorial 
independence.” The investigators conclude that, despite the use of predefined 
standards in their development, important deficiencies exist in the most recent 
clinical treatment guidelines for psoriasis.
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of the Guidelines International Network 
were not included. It is possible that 
other psoriasis treatment guidelines were 
missed as well.
Initially, the evaluation by Nast et al. 
(2009b) was performed independently 
by three members of the method group 
of the European Dermatology Forum 
(EDF) European guideline for psoriasis. 
Thereafter the AGREE-based evaluations 
were discussed among all members of the 
EDF group. The group members involved 
in the development of the evaluated 
guidelines (Dutch, German, and English) 
were permitted to provide additional 
information that was not published. This 
approach ensured that all required infor-
mation was available for assessment. In 
contrast, Tan et al. (2010, this issue) did 
not contact any of the guideline devel-
oper groups. Despite not having access to 
adequate detail, Tan et al. rated some of 
the guidelines higher than did Nast et al. 
(2009b), and they fail to comment on this 
difference in their discussion.
evaluation of implementation
It is important to mention that the means 
by which treatment guidelines are devel-
oped do not guarantee the quality or 
usefulness of their recommendations. A 
high AGREE score does not mean that 
guidelines will necessarily find wide-
spread acceptance or improve the quality 
of care. For this, additional studies are 
necessary, such as those performed 
by Wakkee et al. (2008) examining 
awareness and acceptance of the Dutch 
guidelines and by Nast et al. (2008, 
2009a) evaluating practitioners’ needs 
and changes in patient care.
Patient preferences
Tan and colleagues recommend that 
patients’ preferences be taken into account 
when assembling treatment guidelines. 
We agree, but the evidence concern-
ing patient preferences and satisfaction 
is limited. These studies are hetero-
geneous in terms of patient populations, 
method ology, and outcome mea sures 
used (Lecluse et al., 2009). Instead, we 
believe that patients themselves should be 
included in the development of treatment 
guidelines.
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In their conclusions, the investigators are 
quite pessimistic. Although it is important 
to be aware of shortcomings in treatment 
guidelines, Tan et al. (2010) overlook the 
high domain scores for “scope and pur-
pose,” “clarity and presentation,” and 
positive conclusions about “rigor of devel-
opment.” Not surprisingly, some of the 
guidelines lack some AGREE items. In the 
process of developing guidelines, certain 
decisions will be made that do not favor all 
the AGREE items. These might be attribut-
able to time restrictions and costs, among 
other reasonable factors. We acknowledge, 
however, that deviations from the AGREE 
instrument may be worth noting.
Living guidelines
Regular guideline updates are necessary 
to incorporate new evidence into clinical 
practice. We agree that guidelines should 
mention update procedures. In reality, 
guidelines for psoriasis should be updated 
continually, because it is likely that they 
will be outdated the moment they are pub-
lished. We stress the importance of devel-
oping “living” guidelines that can be updat-
ed as important new evidence becomes 
available. High-quality systematic reviews 
on subjects that play a role in psoriasis care 
could be incorporated in these updates, 
and recommendations should be based on 
the strength of evidence and stakeholders’ 
considerations.
International guidelines should be 
developed cooperatively and then adjusted 
for national and local use. Implementation 
is an important issue because it may be 
difficult for practitioners to choose which 
guidelines to use in daily practice.
Summary
Independent evaluation of existing pso-
riasis treatment guidelines with AGREE 
reveals areas for improvement that should 
be taken into account in future guidelines. 
Assessment of the content and quality of 
evidence used in developing such guide-
lines is the next step to be taken. 
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Clinical Implications
•  In the field of treatment guideline development, standards of quality 
are defined by the AGREE instrument.
•  Cooperation among guideline developers is important with each step in 
quality improvement, thus saving time and money. 
•  Treatment of psoriasis, although individualized with respect to patient 
needs and local options, should balance individualized treatment with 
general, evidence-based best practices.
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Circulating Tumor Cells  
and Melanoma Progression
Xiaowei Xu1 and Jiang F. Zhong2
Circulating tumor cells (CTCs) are cancer cells shed from either a primary tumor or 
its metastases that circulate in the peripheral blood. CTCs are potential seeds for 
metastases, and analyses of CTCs may allow earlier detection of metastasis-capa-
ble malignancy, monitoring for tumor recurrence, and accurate prognostication. 
Studies on CTCs have focused mainly on the detection of epithelial cancer cells. In 
this issue, De Giorgi et al. show that CTCs can be detected in melanoma patients 
using a filtration method, and that a higher percentage of patients with metastatic 
melanoma have detectable CTCs than do patients with primary melanoma.
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Circulating tumor cells (CTCs) are 
cancer cells that have detached from a 
primary tumor or its metastases and cir-
culate in the bloodstream. During tumor 
